[go: up one dir, main page]

DE602006011859D1 - T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon - Google Patents

T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon

Info

Publication number
DE602006011859D1
DE602006011859D1 DE602006011859T DE602006011859T DE602006011859D1 DE 602006011859 D1 DE602006011859 D1 DE 602006011859D1 DE 602006011859 T DE602006011859 T DE 602006011859T DE 602006011859 T DE602006011859 T DE 602006011859T DE 602006011859 D1 DE602006011859 D1 DE 602006011859D1
Authority
DE
Germany
Prior art keywords
individuals
laten
barr
epstein
epitopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602006011859T
Other languages
English (en)
Inventor
Veronique Pancre
Claude Auriault
Stephane Depil
Bernard Maillere
Olivier Morales
Gaetan Munier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Lille 2 Droit et Sante
Original Assignee
Centre National de la Recherche Scientifique CNRS
Commissariat a lEnergie Atomique CEA
Universite Lille 2 Droit et Sante
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Commissariat a lEnergie Atomique CEA, Universite Lille 2 Droit et Sante filed Critical Centre National de la Recherche Scientifique CNRS
Publication of DE602006011859D1 publication Critical patent/DE602006011859D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602006011859T 2005-02-07 2006-02-02 T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon Expired - Lifetime DE602006011859D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0501198A FR2881746B1 (fr) 2005-02-07 2005-02-07 Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
PCT/FR2006/000229 WO2006082313A2 (fr) 2005-02-07 2006-02-02 Epitopes t cd4+ des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus db la population caucasienne et leurs applications

Publications (1)

Publication Number Publication Date
DE602006011859D1 true DE602006011859D1 (de) 2010-03-11

Family

ID=35116028

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006011859T Expired - Lifetime DE602006011859D1 (de) 2005-02-07 2006-02-02 T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon

Country Status (8)

Country Link
US (1) US20090130134A1 (de)
EP (1) EP1861418B1 (de)
JP (1) JP4972562B2 (de)
AT (1) ATE455791T1 (de)
CA (1) CA2596929C (de)
DE (1) DE602006011859D1 (de)
FR (1) FR2881746B1 (de)
WO (1) WO2006082313A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU696167B2 (en) * 1993-10-29 1998-09-03 Trustees Of Boston University Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
CA2324426A1 (en) * 1998-02-11 1999-08-19 Douglas V. Faller Compositions and methods for the treatment of cystic fibrosis
FR2830940B1 (fr) 2001-10-17 2007-06-15 Commissariat Energie Atomique Procede de selection de ligands d'hla-dp4 et ses applications
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
MX2010001779A (es) 2007-08-15 2010-07-06 Circassia Ltd Peptidos para vacunas.
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
MA33899B1 (fr) 2009-12-08 2013-01-02 Hemaquest Pharmaceuticals Inc Procedes et regimes a faible dose pour des troubles des globules rouges
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
CN104394877B (zh) 2012-05-08 2017-11-28 约翰·霍普金斯大学 用于输注短暂植入的同种异体淋巴细胞的选定群体来治疗癌症的方法和组合物
EP3013789B1 (de) 2013-06-28 2020-03-04 Auckland Uniservices Limited Aminosäure- und peptidkonjugate und konjugationsverfahren
MX2017008406A (es) * 2014-12-23 2018-04-24 Anne Brimble Margaret Conjugados de aminoacidos y peptidos y sus usos.
CN108884020A (zh) 2016-02-26 2018-11-23 奥克兰联合服务有限公司 氨基酸及肽共轭物以及共轭过程
EP4650005A3 (de) 2016-07-15 2026-01-28 Viracta Subsidiary, Inc. Histondeacetylasehemmer zur verwendung in der immuntherapie
KR102565256B1 (ko) 2017-02-12 2023-08-08 바이오엔테크 유에스 인크. Hla 기반 방법 및 조성물, 및 이들의 용도
EP3728291A1 (de) * 2017-12-20 2020-10-28 GlaxoSmithKline Biologicals S.A. Epstein-barr-virus-antigenkonstrukte
WO2020132586A1 (en) 2018-12-21 2020-06-25 Neon Therapeutics, Inc. Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
JP2022536256A (ja) 2019-05-31 2022-08-15 ヴィラクタ サブシディアリー，インク． ヒストンデアセチラーゼ阻害剤を用いてウイルス関連癌を治療する方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040157780A1 (en) * 1993-11-29 2004-08-12 Epimmune Inc. CTL inducing peptides from c-erb2 (HER-2/neu)
EP0770090A1 (de) * 1994-07-13 1997-05-02 Cornell Research Foundation, Inc. Protein des epstein-barr virus kernantigen 1 und seine expression und anreicherung
US20020141995A1 (en) * 1997-06-10 2002-10-03 Irvin Charles G. Method for treatment of inflammatory disease
CA2392456A1 (en) * 1999-11-24 2001-05-31 Oklahoma Medical Research Foundation Assays and therapies for latent viral infection
EP1229043A1 (de) * 2001-01-30 2002-08-07 Cyto-Barr B.V. Peptiden abgeleitet VON Epstein Barr virus (EBV) Proteine LMP1, LMP2 und BARF1
GB0214528D0 (en) * 2002-06-24 2002-08-07 Univ Aberdeen Materials and methods for induction of immune tolerance
WO2004007536A2 (en) * 2002-07-16 2004-01-22 Affinium Pharmaceuticals, Inc. Interactions of the epstein-barr virus protein ebna1, and uses thereof
US20070048329A1 (en) * 2002-11-07 2007-03-01 Rajiv Khanna Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
US20040141995A1 (en) * 2002-12-10 2004-07-22 Rongfu Wang MHC class I-restricted and MHC class II-restricted EBNA1 peptides

Also Published As

Publication number Publication date
ATE455791T1 (de) 2010-02-15
WO2006082313A3 (fr) 2007-01-11
JP2008529486A (ja) 2008-08-07
US20090130134A1 (en) 2009-05-21
EP1861418A2 (de) 2007-12-05
FR2881746A1 (fr) 2006-08-11
CA2596929A1 (fr) 2006-08-10
FR2881746B1 (fr) 2007-04-13
CA2596929C (fr) 2015-12-29
WO2006082313A2 (fr) 2006-08-10
EP1861418B1 (de) 2010-01-20
JP4972562B2 (ja) 2012-07-11

Similar Documents

Publication Publication Date Title
DE602006011859D1 (de) T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon
EA201070271A1 (ru) Пептиды для получения вакцины
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
DK2101569T3 (da) Krystallinsk fast rasagilinbase
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
CR20130016A (es) ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
DOP2009000269A (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
NO20074238L (no) Fiksert dosering av HER-antistoffer
MX2009008918A (es) Activacion de celulas que presentan antigeno humano a traves de clec-6.
EA200701918A1 (ru) Белок липокалин
IL182403A0 (en) Systems and methods for ex-vivo organ care
CA2821268C (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
TW200728466A (en) Antibody molecules having specificity for human IL-6
DK1694706T3 (da) Modificeret anti-CD52-antistof
EP1557462A3 (de) Transplant-Akzeptanz induzierende Zellen monocytären ursprungs, sowie deren Herstellung und Verwendung
MA44665B1 (fr) Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques
TW200606177A (en) Glycoprotein VI antibodies and methods thereof
EA201171084A1 (ru) Гели, образующиеся при сдвиговой деформации, и композиции, содержащие гели, образующиеся при сдвиговой деформации
TW200726479A (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
UA107177C2 (uk) Імуногенна композиція цвс2 та спосіб приготування такої композиції
WO2009040674A3 (en) A public and immunogenic cd4+ t cell epitope of the hiv tat protein and its applications
WO2010080188A3 (en) Epitope targeted anthrax vaccine
DK1633373T3 (da) Farmaceutisk sammensætning indeholdende glucan hidrørende fra mikroalger
DK1713438T3 (da) Medicinsk sæbe
ATE525401T1 (de) Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: UNIVERSITE DE LILLE II, LILLE, FR

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, , FR